Infinity Pharmaceuticals | INFI - Current Liabilities


Infinity Pharmaceuticals reported $12.06M in Current Liabilities for its fiscal quarter ending in June of 2023.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Alterity Therapeutics Limited AUD 4.38M 849.82K Jun/2023
Amgen USD 25.49B 3.7B Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Cipla INR 62.97B 8.13B Sep/2025
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 20.28M 300K Sep/2025
CSL USD 4.82B 1.26B Jun/2025
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Grifols EUR 2.53B 182.67M Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
J&J USD 54.13B 3.26B Dec/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Plus Therapeutics USD 10.73M 189K Dec/2023
Roche Holding CHF 28B 421M Dec/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025